

South & Central America Influenza Vaccines Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-based and Cell-based), and Route of Administration (Injection and Nasal Spray)

Market Report | 2022-10-07 | 113 pages | The Insight Partners

AVAILABLE LICENSES:

- Single User Price \$3000.00
- Site Price \$4000.00
- Enterprise Price \$5000.00

Report description:

The influenza vaccines market in South & Central America is expected to grow from US\$ 497.54 million in 2022 to US\$ 736.35 million by 2028. It is estimated to grow at a CAGR of 6.8% from 2022 to 2028.

Emerging Economies

Leading players in the influenza vaccines market focus on expanding their customer reach across emerging markets by expanding their distribution networks and augmenting their manufacturing capabilities. In addition, high investments in life science and healthcare research in emerging countries play a crucial role in upgrading the latest technologies in developing countries. In turn, this supports the inclination toward advanced vaccine development. Key producers of influenza vaccines in Brazil is expected to witness lucrative opportunities in the near future due to the large patient pool and high prevalence of influenza, improving healthcare infrastructure, rising disposable income, and the surge of medical tourism in these countries.

Market Overview

South & Central America influenza vaccines market includes Brazil, Argentina, and Rest of South and Central America. The region held smallest portion of the market in the global analysis. The market for influenza vaccines in the region is expected to have

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

growth opportunities during the forecast period. The influenza vaccines market in the South & Central America region is expected to grow owing to factors such as, an increase in cases of influenza in the region, surge in various research activities in the region, increasing awareness, and rising healthcare expenditure by the countries of the region. Brazil has made huge strides in healthcare sector owing to increasing healthcare expenditure. As per the International Trade Administration (ITA), Brazil is the largest healthcare market in Latin America and spends 9.1% of its GDP in healthcare in 2020. The influenza vaccines market in Brazil is expected to flourish owing to factors such as, surge in vaccination programs in the country, and rising healthcare expenditure by the country. In Brazil, influenza epidemics significantly weigh on the Brazilian healthcare system and society, with an estimated number of ILI cases as high as 83 million in a year. Brazil has one of the most extensive immunization programs worldwide. Since 1999, the influenza vaccines has been provided free of charge to older adults (aged 60 years or more) in the whole count. Public health authorities have then progressively expanded the recommendation to the pediatric age groups by first including, in 2011, children aged from 6 months to under 2yo, then under 5yo in 2016, and in 2019 to all children from 6 months to 6 years of age. Vaccination campaigns are nationwide. These campaigns occur every year for two weeks, before the colder season, in all primary healthcare units. The trivalent and inactivated influenza vaccines is produced by a national laboratory (Instituto Butantan) and administered in private health establishments. As per the Journal of Infection and Public Health, Vaccination coverage remained close to the target of 75% proposed by the World Health Organization. The most relevant factors influencing vaccination have been health-related measures; lifestyle and socioeconomic status also played an essential role in predicting vaccines uptake

South & Central America Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Million)

South & Central America Influenza Vaccines Market Segmentation

The South & Central America Influenza Vaccines Market is segmented into vaccine type, virus type, technology, route of administration, and country.

Based on vaccine type, the South & Central America influenza vaccines market is divided into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment registered the larger market share in 2022.

Based on virus type, the South & Central America influenza vaccines market is segmented into influenza virus type A and influenza virus type B. The influenza virus type A segment held a larger market share in 2022.

Based on technology, the South & Central America influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held a larger market share in 2022.

Based on route of administration, the South & Central America influenza vaccines market is divided into injection and nasal spray. The injection segment held a larger market share in 2022.

Based on country, the market is segmented into Brazil, Argentina, and the rest of South & Central America. Brazil dominated the market share in 2022.

AstraZeneca; GlaxoSmithKline plc.; Hualan Biological Engineering Inc.; Mitsubishi Chemical Group Corporation; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd are the leading companies operating in the influenza vaccines market in South & Central America.

Table of Contents:

TABLE OF CONTENTS

1. Introduction

- 1.1 Study Scope
- 1.2 The Insight Partners Research Report Guidance
- 1.3 Market Segmentation
 - 1.3.1 South & Central America Influenza Vaccines Market - By Vaccine Type
 - 1.3.2 South & Central America Influenza Vaccines Market - By Virus Type
 - 1.3.3 South & Central America Influenza Vaccines Market - By Technology
 - 1.3.4 South & Central America Influenza Vaccines Market - By Route Of Administration
 - 1.3.5 South & Central America Influenza Vaccines Market - By Country
2. Influenza Vaccines Market - Key Takeaways
3. Research Methodology
 - 3.1 Coverage
 - 3.2 Secondary Research
 - 3.3 Primary Research
4. South & Central America Influenza Vaccines Market Market Landscape
 - 4.1 Overview
 - 4.2 PEST Analysis
 - 4.2.1 South & Central America PEST Analysis
 - 4.3 Experts Opinion
5. South & Central America Influenza Vaccines Market Key Market Dynamics
 - 5.1 Market Drivers
 - 5.1.1 Increase in Government Support to Promote Influenza Vaccination
 - 5.2 Market Restraints
 - 5.2.1 High Cost of Vaccine Development
 - 5.3 Market Opportunities
 - 5.3.1 Emerging Economies
 - 5.4 Future Trends
 - 5.4.1 Strong Pipeline Candidates for Influenza Vaccines
 - 5.5 Impact Analysis
6. Influenza Vaccine Market - South & Central America Analysis
 - 6.1 South & Central America Influenza Vaccines Market Revenue Forecasts And Analysis
7. South & Central America Influenza Vaccines Market- By Vaccine Type
 - 7.1 Overview
 - 7.2 South & Central America Influenza Vaccines Market, By Vaccine Type 2022 & 2028 (%)
 - 7.3 Quadrivalent Vaccines
 - 7.3.1 Overview
 - 7.3.2 South & Central America Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
 - 7.4 Trivalent Vaccines
 - 7.4.1 Overview
 - 7.4.2 South & Central America Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
8. South & Central America Influenza Vaccines Market- By Virus Type
 - 8.1 Overview
 - 8.2 South & Central America Influenza Vaccines Market, By Virus Type 2022 & 2028 (%)
 - 8.3 Influenza Virus Type A
 - 8.3.1 Overview
 - 8.3.2 South & Central America Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
 - 8.4 Influenza Virus Type B
 - 8.4.1 Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.4.2 South & Central America Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
- 9. South & Central America Influenza Vaccines Market By Technology
 - 9.1 Overview
 - 9.2 South & Central America Influenza Vaccines Market, By Technology 2022 & 2028 (%)
 - 9.3 Egg-Based
 - 9.3.1 Overview
 - 9.3.2 South & Central America Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
 - 9.4 Cell-Based
 - 9.4.1 Overview
 - 9.4.2 South & Central America Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
- 10. South & Central America Influenza Vaccines Market- By Route of Administration
 - 10.1 Overview
 - 10.2 South & Central America Influenza Vaccines Market, By Route of Administration 2022 & 2028 (%)
 - 10.3 Injection
 - 10.3.1 Overview
 - 10.3.2 South & Central America Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
 - 10.4 Nasal Spray
 - 10.4.1 Overview
 - 10.4.2 South & Central America Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
- 11. South & Central America Influenza Vaccines Market Country Analysis
 - 11.1 South & Central America Influenza Vaccine Market Revenue and Forecasts to 2028
 - 11.1.1 Overview
 - 11.1.3 South & Central America: Influenza Vaccine Market, by Country, 2022 & 2028 (%)
 - 11.1.3.1 Brazil: Influenza Vaccine Market - Revenue and Forecast to 2028 (USD Million)
 - 11.1.3.1.1 Overview
 - 11.1.3.1.2 Brazil: Influenza Vaccine Market - Revenue and Forecast to 2028 (USD Million)
 - 11.1.3.1.3 Brazil: Influenza Vaccine Market, by Vaccine Type, 2019-2028 (USD Million)
 - 11.1.3.1.4 Brazil: Influenza Vaccine Market, by Virus Type, 2019-2028 (USD Million)
 - 11.1.3.1.5 Brazil: Influenza Vaccine Market, by Technology, 2019-2028 (USD Million)
 - 11.1.3.1.6 Brazil: Influenza Vaccine Market, by Route of Administration, 2019-2028 (USD Million)
 - 11.1.3.2 Argentina: Influenza Vaccine Market - Revenue and Forecast to 2028 (USD Million)
 - 11.1.3.2.1 Overview
 - 11.1.3.2.2 Argentina: Influenza Vaccine Market - Revenue and Forecast to 2028 (USD Million)
 - 11.1.3.2.3 Argentina: Influenza Vaccine Market, by Vaccine Type, 2019-2028 (USD Million)
 - 11.1.3.2.4 Argentina: Influenza Vaccine Market, by Virus Type, 2019-2028 (USD Million)
 - 11.1.3.2.5 Argentina: Influenza Vaccine Market, by Technology, 2019-2028 (USD Million)
 - 11.1.3.2.6 Argentina: Influenza Vaccine Market, by Route of Administration, 2019-2028 (USD Million)
 - 11.1.3.3 Rest of South & Central America: Influenza Vaccine Market - Revenue and Forecast to 2028 (USD Million)
 - 11.1.3.3.1 Overview
 - 11.1.3.3.2 Rest of South & Central America: Influenza Vaccine Market - Revenue and Forecast to 2028 (USD Million)
 - 11.1.3.3.3 Rest of South & Central America: Influenza Vaccine Market, by Vaccine Type, 2019-2028 (USD Million)
 - 11.1.3.3.4 Rest of South & Central America: Influenza Vaccine Market, by Virus Type, 2019-2028 (USD Million)
 - 11.1.3.3.5 Rest of South & Central America: Influenza Vaccine Market, by Technology, 2019-2028 (USD Million)
 - 11.1.3.3.6 Rest of South & Central America: Influenza Vaccine Market, by Route of Administration, 2019-2028 (USD Million)
 - 12. South & Central America Influenza Vaccine Market -Industry Landscape
 - 12.1 Overview
 - 12.2 Inorganic Growth Strategies

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.2.1 Overview
- 12.3 Organic Growth Strategies
 - 12.3.1 Overview
- 13. Company Profiles
 - 13.1 SEQIRUS
 - 13.1.1 Key Facts
 - 13.1.2 Business Description
 - 13.1.3 Products and Services
 - 13.1.4 Financial Overview
 - 13.1.5 SWOT Analysis
 - 13.1.6 Key Developments
 - 13.2 Sanofi
 - 13.2.1 Key Facts
 - 13.2.2 Business Description
 - 13.2.3 Products and Services
 - 13.2.4 Financial Overview
 - 13.2.5 SWOT Analysis
 - 13.2.6 Key Developments
 - 13.3 GlaxoSmithKline plc.
 - 13.3.1 Key Facts
 - 13.3.2 Business Description
 - 13.3.3 Products and Services
 - 13.3.4 Financial Overview
 - 13.3.5 SWOT Analysis
 - 13.3.6 Key Developments
 - 13.4 Hualan Biological Engineering Inc.
 - 13.4.1 Key Facts
 - 13.4.2 Business Description
 - 13.4.3 Products and Services
 - 13.4.4 Financial Overview
 - 13.4.5 SWOT Analysis
 - 13.4.6 Key Developments
 - 13.5 Mitsubishi Chemical Group Corporation
 - 13.5.1 Key Facts
 - 13.5.2 Business Description
 - 13.5.3 Products and Services
 - 13.5.4 Financial Overview
 - 13.5.5 SWOT Analysis
 - 13.5.6 Key Developments
 - 13.6 Serum Institute of India Pvt. Ltd
 - 13.6.1 Key Facts
 - 13.6.2 Business Description
 - 13.6.3 Products and Services
 - 13.6.4 Financial Overview
 - 13.6.5 SWOT Analysis
 - 13.6.6 Key Developments
 - 13.7 MYLAN N.V.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
- 13.8 AstraZeneca
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
- 14. Appendix
- 14.1 About The Insight Partners
- 14.2 Glossary of Terms

South & Central America Influenza Vaccines Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-based and Cell-based), and Route of Administration (Injection and Nasal Spray)

Market Report | 2022-10-07 | 113 pages | The Insight Partners

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$3000.00
	Site Price	\$4000.00
	Enterprise Price	\$5000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-06"/>
		Signature	<input type="text"/>